Key Highlights

  • AngioDynamics (NASDAQ:ANGO) reports fiscal first quarter 2027 before the market opens on Thursday, October 8, with its call at 8:00 a.m. ET. Published consensus is a loss of about USD 0.11 per share on USD 81 million of revenue.
  • Fourth quarter net sales were USD 86.6 million, up 8.0 percent pro forma, with Med Tech up 16.7 percent to USD 41.8 million and Med Device up 1.1 percent to USD 44.8 million.
  • Fiscal 2027 guidance calls for net sales of USD 336 million to USD 341 million, an adjusted loss of USD 0.29 to USD 0.24 per share and adjusted EBITDA of USD 13 million to USD 16 million.
  • The company ended May 31, 2026 with USD 53.9 million of cash and no debt, and fiscal 2026 adjusted EBITDA was USD 13.2 million on USD 320.2 million of net sales.

What Is Due and When

AngioDynamics (NASDAQ:ANGO) will report results for the first quarter of fiscal 2027, which ended August 31, 2026, before the open on Thursday, October 8. The company said so in a September 28 notice and will hold a call at 8:00 a.m. ET. Published consensus, from the user's screener and unverified, is a loss of about USD 0.11 per share on USD 81 million of revenue. That compares with an adjusted loss of USD 0.07 and USD 86.6 million in the fourth quarter, and an adjusted loss of USD 0.10 on USD 75.7 million a year earlier. Revenue of USD 81 million would be about 7 percent above the year-ago figure, simple arithmetic on two published numbers. The latest quote of USD 14.59 gives a Market Value near USD 614 million.

Med Tech Carries the Story

AngioDynamics (NASDAQ:ANGO) is shifting toward Med Tech, which holds platform products such as Auryon, AlphaVac and NanoKnife. Med Tech grew 18.4 percent to USD 150.0 million in fiscal 2026 while Med Device, the older portfolio, grew 2.5 percent to USD 170.2 million. A published analysis put Auryon at USD 66.9 million, up 17.7 percent, and AlphaVac at USD 15.5 million, up 44.1 percent, though those figures were not checked against the filing. Gross Margin was 54.0 percent in the fourth quarter and 54.6 percent for the year. Guidance assumes Med Tech growth of 12 percent to 15 percent, which implies a slowdown from the recent pace, and the first quarter is the first test of that deceleration.

Risks and What to Watch

Tariff expenses were reported at USD 4.8 million in fiscal 2026, trimming gross margin by about 151 basis points, and fourth quarter sales and Marketing expense rose 17.7 percent while Research and Development rose 24.1 percent, according to a published analysis. Heavier spending could delay operating leverage, and the first quarter is seasonally the weakest for cash. Watch Med Tech growth against 12 percent to 15 percent, gross margin against the 54 percent to 55 percent guide and any change to the USD 336 million to USD 341 million range. A Category I billing code for irreversible electroporation in pancreatic cancer is slated for January 2027, a possible NanoKnife catalyst that management may discuss.

Where Things Stand

AngioDynamics (NASDAQ:ANGO) is set to report a modest revenue rise on a still loss-making quarter, with consensus near USD 81 million of sales and a loss of USD 0.11 per share. The balance of evidence is mixed: Med Tech is growing fast and the Balance Sheet is debt-free, but spending is rising and tariffs weigh on margin. The next catalyst is the 8:00 a.m. ET call on October 8. This is informational analysis, not Investment advice, and results can differ from expectations.